Deliargyris Efthymios has filed 16 insider transactions across 1 company since July 2023.
Most recent transaction: a grant/award of 70000 shares of Cytosorbents Corp ($CTSO) on August 08, 2025.
Activity breakdown: 2 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 8, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Common Stock | 70000 | $0.00 | 473,025.0000 | 67,166,377 | 17.37% | 0.10% |
| Aug. 8, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (Right to Buy) | 95000 | $0.00 | 95,000.0000 | 67,166,377 | 9999.99% | 0.14% |
| Jan. 17, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | X | Common Stock | 16233 | $1.00 | 403,025.0000 | 54,434,609 | 4.20% | 0.03% |
| Jan. 17, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | X | Subscription Rights (right to buy) | 16233 | $0.00 | 0.0000 | 54,434,609 | 100.00% | 0.03% |
| Jan. 17, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | J | Series A Right Warrants | 16233 | $0.00 | 16,233.0000 | 54,434,609 | 9999.99% | 0.03% |
| Jan. 17, 2025 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | J | Series B Right Warrants | 16233 | $0.00 | 16,233.0000 | 54,434,609 | 9999.99% | 0.03% |
| Oct. 4, 2024 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (Right to Buy) | 100000 | $0.00 | 100,000.0000 | 54,453,006 | 9999.99% | 0.18% |
| Oct. 4, 2024 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (Right to Buy) | 50000 | $0.00 | 50,000.0000 | 54,453,006 | 9999.99% | 0.09% |
| April 2, 2024 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Common Stock | 61000 | $0.00 | 409,433.0000 | 54,434,609 | 17.51% | 0.11% |
| April 2, 2024 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (Right to Buy) | 86000 | $0.00 | 86,000.0000 | 54,434,609 | 9999.99% | 0.16% |
| March 29, 2024 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (Right to Buy) | 47088 | $0.00 | 47,088.0000 | 44,656,391 | 9999.99% | 0.11% |
| Dec. 13, 2023 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | P | Common Stock | 22557 | $1.33 | 348,433.0000 | 44,373,969 | 6.92% | 0.05% |
| Dec. 13, 2023 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | P | Common Stock Warrant (Right to Buy) | 7894 | $0.00 | 7,894.0000 | 44,373,969 | 9999.99% | 0.02% |
| July 7, 2023 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Common Stock | 55000 | $0.00 | 331,648.0000 | 44,015,380 | 19.88% | 0.12% |
| July 7, 2023 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (right to buy) | 78000 | $0.00 | 78,000.0000 | 44,015,380 | 9999.99% | 0.18% |
| July 7, 2023 | Cytosorbents Corp | $CTSO | Deliargyris Efthymios | Chief Medical Officer | A | Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 44,015,380 | 9999.99% | 0.09% |